AKRO Similar Chart Price Prediction
The price of AKRO is predicted to go up 15.13%, based on the high correlation periods with SINT. The similarity of these two price pattern on the periods is 99.4%.
AKRO
SINT
Up: 15.13%Similarity: 99.4%
AKRO Revenue Forecast
AKRO EPS Forecast
AKRO FAQs
What is bull’s view on AKRO?
What is bear's view on AKRO?
What is AKRO eps forecast for next quarter？
AKRO Analyst's Forecast
Eliana Merle
UBS
Strong Buy
2025-01-31
Price Target
$42 → $109
Upside
+104.2%
UBS raised the firm's price target on Akero Therapeutics to $109 from $42 and keeps a Buy rating on the shares. Akero reported "strong" results from the 96-week biopsy data from the Phase 2b SYMMETRY trial of FGF21efruxifermin in metabolic dysfunction-associated steatohepatitis F4s, with efruxifermin 50mg resulting in a 24% effect size in fibrosis improvement over placebo at 96 weeks in a completers analysis, and in an ITT analysis, the effect size was 17%, the analyst tells investors in a research note. The firm still sees potential upside from here, and thinks the updated data is supportive of a significant opportunity for FGF21s as potentially the most potent anti-fibrotic class in MASH.
Alexandria Hammond
B of A Securities
Hold → Strong Buy
2025-01-30
Price Target
$35 → $63
Upside
+12.38%
Michael Ulz
Morgan Stanley
Buy
2025-01-28
Price Target
$46 → $96
Upside
+92.15%
